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Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is
a postinfectious severe acute respiratory syndrome coronavirus 2 (SARSCoV-2)–related complication that has disproportionately affected racial/ethnic minority children. We conducted a pilot study to investigate risk factors
for MIS-C aiming to understand MIS-C disparities.
Methods: This case-control study included MIS-C cases and SARS-CoV2-positive outpatient controls less than 18 years old frequency-matched
4:1 to cases by age group and site. Patients hospitalized with MIS-C were
admitted between March 16 and October 2, 2020, across 17 pediatric
hospitals. We evaluated race, ethnicity, social vulnerability index (SVI),
insurance status, weight-for-age and underlying medical conditions as risk
factors using mixed effects multivariable logistic regression.

Results: We compared 241 MIS-C cases with 817 outpatient SARS-CoV2-positive at-risk controls. Cases and controls had similar sex, age and
U.S. census region distribution. MIS-C patients were more frequently
previously healthy, non-Hispanic Black, residing in higher SVI areas,
and in the 95th percentile or higher for weight-for-age. In the multivariable analysis, the likelihood of MIS-C was higher among non-Hispanic
Black children [adjusted odds ratio (aOR): 2.07; 95% CI: 1.23–3.48].
Additionally, SVI in the 2nd and 3rd tertiles (aOR: 1.88; 95%
CI: 1.18–2.97 and aOR: 2.03; 95% CI: 1.19–3.47, respectively) were
independent factors along with being previously healthy (aOR: 1.64; 95%
CI: 1.18–2.28).
Conclusions: In this study, non-Hispanic Black children were more likely to
develop MIS-C after adjustment for sociodemographic factors, underlying
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medical conditions, and weight-for-age. Investigation of the potential contribution of immunologic, environmental, and other factors is warranted.
Key Words: children, coronavirus disease 2019, multisystem inflammatory
syndrome in children, SARS-CoV-2, health disparities, risk factors
(Pediatr Infect Dis J 2022;41:891–898)

INTRODUCTION
Multisystem inflammatory syndrome in children (MIS-C)
is a hyperinflammatory condition associated with immune dysregulation and multiple organ system involvement that occurs
after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019
(COVID-19).1–3 MIS-C is a distinct syndrome, although some clinical features overlap with other hyperinflammatory syndromes, such
as Kawasaki disease and toxic shock syndrome,4–7 and with acute
COVID-19 critical illness in children with multiorgan dysfunction.8
Immune risk factors that may predispose children to developing MIS-C after SARS-CoV-2 infection are under investigation;
however, there is a consistent overrepresentation of children from
minority populations relative to the estimated population distribution of reporting countries.4,5,8–12 A study published with data
from 3 academic centers in Boston, Massachusetts, reported that
higher risk for MIS-C in Black and Hispanic children remained
after adjusting for the association between socioeconomic status
and social vulnerability index (SVI), a measure developed by the
U.S. Centers for Disease Control and Prevention (CDC).13 A CDC
report on MIS-C national surveillance data has also noted that
non-Hispanic Black children had higher odds of more severe MISC, with higher frequencies of intensive care unit admission and
decreased cardiac function.14 Given the higher frequency of obesity
and potential exposure to environmental contaminants in socially
vulnerable communities,15 it is unclear if these or other factors may
in part explain higher risk of MIS-C in Black children.
Understanding why health disparities by race and ethnicity are associated with MIS-C is a public health priority. We conducted this retrospective multicenter pilot study to inform a future
in-depth MIS-C risk factor investigation. We included sites from
the Overcoming COVID-19 multicenter U.S. network to identify
MIS-C cases and at-risk SARS-CoV-2-positive outpatient controls
to explore risk factors associated with MIS-C. Demographic characteristics, SVI, specific underlying medical conditions, and high
weight-for-age were assessed to determine how they may independently contribute to the likelihood of MIS-C after SARS-CoV-2
infection.

METHODS
Overcoming COVID-19 is a multicenter pediatric public
health surveillance registry of hospitalized children with severe
COVID-19 and MIS-C from >60 hospitals in 31 states across the
USA, and MIS-C case ascertainment methods have been previously
reported in detail.8,11 This retrospective case-control analysis was
designed as a pilot to inform a future more expansive public health
investigation of risk factors for MIS-C. This investigation included
MIS-C patients from 17 participating hospitals, selected based on
those with the highest number of MIS-C cases reported through the
Overcoming COVID-19 registry as of June 24, 2020, to maximize
the total number of patients available for comparison. We aimed to
enroll MIS-C at-risk outpatient controls in a 4:1 ratio. All information was extracted from patient medical records using common data
elements for cases and controls.
This protocol was reviewed and approved by the Boston Children’s Hospital Institutional Review Board, which served as the single
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institutional review board, by participating sites, and by the CDC
where it was determined to meet the requirements of public health
surveillance per 45 CFR §46.101(b)(4) and exempt from patient
informed consent per 45 CFR §164.506(d)(2)(ii)(B). This report conforms to the Strengthening the Reporting of Observational Studies in
Epidemiology reporting guidelines for case-control studies.16

Study Population
Cases included children less than 18 years of age hospitalized for MIS-C. Outpatient control patients (controls) were
considered eligible if they had a positive reverse transcription–
polymerase chain reaction (RT-PCR) test for SARS-CoV-2 infection at an outpatient setting during a medical visit with a clinical
note and were not hospitalized for any suspected SARS-CoV-2–
related complications in the study period. Hospital admission or
test positivity occurred for cases and controls, respectively, from
March 16, 2020 to October 2, 2020, reflecting a time period before
COVID-19 vaccine availability. Cases were identified retrospectively from the Overcoming COVID-19 registry if they were less
than 18 years of age and otherwise met the following MIS-C
clinical criteria, adapted from the CDC case definition:8 (1) severe
disease requiring hospitalization; (2) fever ≥38°C for ≥24 hours;
(3) multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurologic);
(4) any abnormal laboratory value reflecting evidence of inflammation (elevated C-reactive protein, erythrocyte sedimentation rate,
fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase, or interleukin 6, elevated neutrophils, reduced lymphocytes
and low albumin) and (5) laboratory evidence of current or recent
SARS-CoV-2 infection by RT-PCR, serology or antigen test.
Controls were matched by age group (0–4 years, 5–12
years and 13–17 years) within each site. Outpatient settings were
emergency departments, outpatient clinics and telemedicine visits at sites associated with the 17 participating hospitals. Patients
with positive testing who were not evaluated by a clinician were
excluded.

Exposures and Outcomes Measured
Primary exposures of interest included demographic and
socioeconomic characteristics, weight-for-age as a proxy for obesity and underlying medical conditions. The primary outcome of
interest was diagnosis of MIS-C.17 Factors considered as potential
MIS-C risk factors in each model included sex, age (as a continuous variable), race, ethnicity, underlying health conditions, health
insurance status and the CDC SVI (Supplemental Digital Content
2, http://links.lww.com/INF/E810), a composite index of 15 census variables broadly reflective of social conditions and community characteristics.15,18 Patients were considered to be previously
healthy if they had no documented medical diagnoses and were not
taking prescription medications for a chronic condition.
Race and ethnicity information was collected from the
medical record and categorized as non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, Hispanic, other, and unknown.19
Using established methods, persons of Hispanic ethnicity were
classified as such regardless of race.19 SVI scores15,18 were linked
to patients by the first four digits of their zip code (full zip code
was not included in the registry to protect patient confidentiality),
extrapolated to census tract using the U.S. Postal Service tract-tozip code crosswalk file from the U.S. Department of Housing and
Urban Development, and divided into tertiles (0–0.32, 0.33–0.66
and 0.67–1.00).20 Where a zip code matched to multiple census
tracts, a weighted average for SVI was computed using tract-based
population estimates derived from the American Community Survey 2014–2018 estimates,21 embedded within the SVI dataset.
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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Weight-for-age was used as a proxy to assign potential obesity status in lieu of body mass index given insufficient data; height
was not available for many outpatient controls. This method also
allowed inclusion of patients less than 2 years for whom obesity
cannot be defined. There is, however, high concordance of weightfor-age with measures of overweight and obesity.22 Weight-for-age
percentiles were calculated based on the 2000 CDC Growth Charts
for persons from 0 to less than 20 years of age.23,24 Biologically
implausible weight-for-age values based on extreme Z-scores of
less than −5 and above 8 were excluded. Weight-for-age percentile
categories included 0–89th, 90–94th and 95–100th, in accordance
with established weight-for-age percentile cut-points.24 A sensitivity analysis was conducted excluding children under 2 years of age,
for whom obesity is not defined.

Statistical Analysis
This investigation was powered a priori to detect an OR of
2.04 given an exposure prevalence among controls of 10% and a
ratio of four controls to each case, with 242 cases and 968 targeted
controls using Bonferroni correction of alpha to 0.01 for multiple
comparisons; however, all findings were considered exploratory,
regardless of significance thresholds. Patient demographic, socioeconomic and clinical characteristics between cases and controls
were compared using Kruskal-Wallis tests for nonparametric comparison of medians, Mantel-Haenszel χ2 tests for comparisons of
frequencies, and Fisher Exact tests for comparisons of frequencies
where cell sizes were less than 5. Multicollinearity of potential
covariates was assessed using Pearson correlation coefficients and
variance inflation factors,25 resulting in removal of underlying
oncologic, gastrointestinal, hepatic or hematologic disease from the
full model. Factors were retained in multivariable logistic regression models if their removal altered the full model effect estimate
by greater than or equal to 10%. Hospital site was included as a
random effect to account for between-site heterogeneity. Both SVI
and weight-for-age were evaluated for their potential to modify the
effect of race/ethnicity on the odds of developing MIS-C. Full models incorporated these interaction terms regardless of significance;
however, race/ethnicity was stratified by weight-for-age percentile
groups and by SVI tertile.
To assess the effect of missing data on the outcome, we
performed multivariable multiple imputation by fully conditional
specification26 using 20 imputed datasets as a sensitivity analysis;
postimputation results are presented in the supplement. Site, race,
ethnicity, weight-for-age, SVI score and insurance status were
included in each imputation model. For all descriptive and modeled estimates derived from imputed data, pooled estimates were
calculated into a final point estimate.
All data cleaning, management, and analysis were performed in R Studio Version 1.2.5033 and SAS version 9.4 (SAS
Institute, Cary, NC).

RESULTS
A total of 241 MIS-C cases matched to at least 1 SARS-CoV2-positive outpatient control from 17 pediatric hospitals (Supplemental Digital Content 3 and 4, http://links.lww.com/INF/E810). After
matching to cases by site and age group, 817 outpatient controls were
included. All 241 patients had at least 1 positive SARS-CoV-2 test.
Among them, 136 (56.4%) were positive for SARS-CoV-2 infection
by RT-PCR and 194 (80.5%) were positive for SARS-CoV-2 antibody; 105 patients (43.6%) tested positive both by RT-PCR and for
SARS-CoV-2 antibody. Additionally, case-patients had evidence of
multisystem organ involvement (median: 4 organ systems; interquartile range: 3–5) and systemic inflammation (Supplemental Digital
Content 5A and 5B, http://links.lww.com/INF/E810). All controls
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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were positive for SARS-CoV-2 by RT-PCR and enrolled from emergency departments (60.2%), outpatient clinics (11.6%) or telemedicine with separate testing (18.7%); testing site was not reported for
9.3% of controls.
Table 1 shows the comparison of cases to controls for demographic and socioeconomic characteristics. Sex, age and health
insurance status did not significantly differ between cases and outpatient controls. A higher proportion of MIS-C cases than controls
were non-Hispanic Black [88 (40.2%) vs. 226 (30.1%)], reflecting differences in the racial/ethnic distribution between groups (P
= 0.03). Cases were observed to be more likely to reside in areas
with moderate or high SVI; that is in areas with more social vulnerability. Among all enrolled patients, the distribution of SVI scores
differed significantly by race (<0.001) with non-Hispanic Black
and Hispanic patients having the highest SVI (Fig. 1A). More
non-Hispanic White and non-Hispanic Asian patients used private
insurance and more non-Hispanic Black and Hispanic patients used
public insurance (Fig. 1B). Although cases were more likely to be
previously healthy than the control patients, a higher proportion of
cases were in the greater than or equal to 95 percentile for weightfor-age after excluding children less than 2 years of age from the
analysis (Supplemental Digital Content 6, http://links.lww.com/
INF/E810). Notably, while weight-for-age was used as a proxy for
obesity, high concordance between weight-for-age and BMI-forage was observed for 214 MIS-C case-patients more than 2 years of
age for whom both weight and height data were available (Supplemental Digital Content 7 and 8, http://links.lww.com/INF/E810).
The most common underlying respiratory condition for cases and
controls was asthma.
In multivariable models, non-Hispanic Black children were
more likely to have MIS-C [adjusted odds ratio (aOR): 2.07 (95%
CI: 1.23–3.48)], as were children residing in moderate SVI areas
[aOR: 1.88 (95% CI: 1.18–2.97)] and high SVI areas [aOR: 2.03
(95% CI: 1.19–3.47)] (Table 2). In general, children who were previously healthy had greater odds of MIS-C [aOR: 1.64 (95% CI:
1.18–2.28)]. While weight-for-age was not independently associated with MIS-C when including children less than 2 years of age
(Table 2), after excluding these children in a sensitivity analysis,
those in greater than or equal to 95th weight-for-age percentile had
higher odds of developing MIS-C compared with children in the
0–89th percentile [aOR: 1.76 (1.20–2.59); Supplemental Digital
Content 6, http://links.lww.com/INF/E810]. Stratified analyses
indicated that among children residing in areas with low SVI,
greater odds of MIS-C were observed among non-Hispanic Black
children [aOR: 8.47 (95% CI: 2.24–32.03)] compared with nonHispanic White children (Table 3). The odds of MIS-C among nonHispanic Black children did not appear to differ by weight-for-age
percentile (Table 3).
There were 22 (9.1%) cases and 65 (8.0%) outpatient
controls missing both race and ethnicity. The distribution of demographic and socioeconomic characteristics among cases and controls after imputation of missing data are shown in Supplemental
Digital Content 9, http://links.lww.com/INF/E810. After imputing
missing data, our findings were similar (Supplemental Digital Content 9–11, http://links.lww.com/INF/E810).

DISCUSSION
In this multicenter pilot case-control investigation, MIS-C
was more likely among non-Hispanic Black children infected
with SARS-CoV-2 than non-Hispanic White children after controlling for SVI, weight-for-age percentile, and health insurance
status. Social vulnerability was highest in non-Hispanic Black
and Hispanic children, but it was independently associated with
MIS-C after adjusting for demographic factors and presence of
www.pidj.com |
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TABLE 1. Distribution of Socioeconomic, Demographic, and Clinical Characteristics Among MIS-C Case-Patients
and SARS-CoV-2-Positive Outpatient Controls (N = 1058)
Patients, No., %
Characteristic
Sex
Female
Age
Mean (SD)
Median (IQR)
0–4 years
5–12 years
13–17 years
Race and ethnicity (N = 971)†
Non-Hispanic White
Non-Hispanic Black
Non-Hispanic Asian
NH/PI, AI/AN, non-Hispanic Multiracial
Hispanic/Latino of any race
Health insurance (N = 1008)‡
Public (eg, Medicaid)
Private
Uninsured/self-pay
Census region
Region 1: Northeast
Region 2: Midwest
Region 3: South
Region 4: West
Social vulnerability index (N = 1053)§
Median (IQR)
  Low (Score: 0–32)
  Moderate (Score: 33–66)
  High (Score: 67–100)
Weight-for-age percentile (N = 1027)¶
Median (IQR = Q3–Q1)
  0–89th percentile
  90th–94th percentile
  95th–100th percentile
Respiratory system disorder
Asthma
Nonrespiratory system disorder
Cardiovascular disease
Neurologic or neuromuscular disorder
Rheumatologic or immunologic disorder
Hematologic disorder
Gastrointestinal or hepatic disorder
Endocrine disorder
Metabolic or confirmed or suspected genetic disorder
Active or prior oncologic disorder

Cases (N = 241)

Controls (N = 817)

P*

103 (42.7)

390 (47.7)

0.17

9.0 (5.1)
8.7 (4.7–13.5)
62 (25.7)
110 (45.6)
69 (28.6)

8.8 (5.6)
9.3 (3.8–13.6)
232 (28.4)
357 (43.7)
228 (27.9)

0.51
0.51
0.71

28 (12.8)
88 (40.2)
8 (3.7)
3 (1.4)
92 (42.0)

156 (20.7)
226 (30.1)
25 (3.3)
18 (2.4)
327 (43.5)

0.03

143 (59.3)
71 (29.5)
13 (5.4)

500 (61.2)
259 (31.7)
22 (2.7)

0.15

109 (45.2)
37 (15.4)
70 (29.0)
25 (10.4)

311 (38.1)
150 (18.4)
260 (31.8)
96 (11.8)

0.25

54.9 (42.7–65.6)
31 (12.9)
151 (62.7)
57 (23.7)

51.4 (35.8–62.6)
178 (21.8)
471 (57.6)
165 (20.2)

0.01
0.02

86.5 (55.7–97.4)
135 (56.0)
31 (12.9)
75 (31.1)
33 (13.7)
27 (11.2)
19 (7.9)
6 (2.5)
12 (5.0)
5 (2.1)
6 (2.5)
11 (4.6)
6 (2.5)
5 (2.1)
5 (2.1)

78.7 (50.4–94.7)
508 (64.6)
89 (11.3)
189 (24.1)
166 (20.3)
152 (18.6)
81 (9.9)
25 (3.1)
32 (3.9)
29 (3.5)
23 (2.8)
41 (5.0)
16 (2.0)
28 (3.4)
9 (1.1)

0.03
0.05
0.02
0.01
0.34
0.64
0.47
0.25
0.79
0.77
0.61
0.29
0.10

*
Significance was assessed using Satterthwaite t tests for comparison of means, Kruskal-Wallis test for Nonparametric comparison of medians, Mantel-Haenszel χ2 tests for
comparisons of frequencies, and Fisher Exact test for comparisons of frequencies where cell sizes <5.
†
Information on race or ethnicity was missing for 87 patients included in this analysis (22 cases and 65 controls). These missing values were excluded from the denominator.
‡
Information on health insurance status was missing for 50 patients included in this analysis (14 cases and 36 controls).
§
Information on zip code of residence, used to determine SVI score, was missing for 5 patients (2 cases and 3 controls).
¶
Information on patient weight was missing for 31 controls.
AI/AN indicates American Indian/Alaskan Native; IQR, interquartile range; MIS-C, multisystem inflammatory syndrome in children; NH/PI, Native Hawaiian/Pacific Islander;
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.

underlying conditions. Over 80% of MIS-C patients were previously healthy, so underlying health conditions were not a risk factor
for MIS-C. While non-Hispanic Black children are at disproportionately higher risk of SARS-CoV-2 infection,27–29 our analysis
suggests these children were also more likely to develop MIS-C
after infection, as we compared MIS-C cases to an age-matched
control group of SARS-CoV-2-positive children potentially at risk
for MIS-C. While Hispanic children did not have increased odds of
MIS-C compared with outpatient controls with SARS-CoV-2 infection, they were highly represented in both study arms. This analysis
adds to the growing body of evidence demonstrating the disproportionate impact of COVID-19 on minority communities.30–33
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A combination of unmeasured factors and social determinants,
such as household and localized environmental characteristics, diet
and general nutrition, host factors that alter immune cell recognition of SARS-CoV-2,4 and chronic stress-induced hyperinflammation, may play a large contributory role in the susceptibility to and
pathophysiology of MIS-C.34
In contrast to a prior case-control study,13 we cannot attribute the higher frequency of MIS-C in non-Hispanic Black children
to increased risk of SARS-CoV-2 infection. As race and ethnicity
are social constructs, we attempted to use SVI to interpret the associations within the broader context of social inequities and related
social determinants of health.35 In the US, census tract of residence
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 1. A: Distribution of social vulnerability index scores, by race and ethnicity. B: Proportion of patients with Medicaid,
private insurance, or no insurance/self-pay, by race and ethnicity, among all enrolled patients.
TABLE 2. Adjusted ORs for MIS-C by Exposure Category (N = 973)
Cases
Exposure Category
Sex
Male
Female
Race and ethnicity
Non-Hispanic Black
Non-Hispanic Asian
NH/PI, AI/AN, non-Hispanic Multiracial
Hispanic/Latino of any race
Non-Hispanic White
Health insurance
U.S. Government (eg, Medicaid)
Uninsured/self-pay
Private
Social vulnerability index
High (Score: 67–100)
Moderate (Score: 33–66)
Low (Score: 0–32)
Weight-for-age percentile
95th–100th percentile
90th–94th percentile
0–89th percentile
Underlying medical conditions‡
Respiratory system disorder
Nonrespiratory system disorder
Previously healthy

N = 225

Controls
N = 748

Adjusted† OR (95% CI)

128 (56.9)
97 (43.1)

385 (51.5)
363 (48.5)

1.34 (0.98–1.82)
REF

81 (36.0)
8 (3.6)
23 (10.2)
85 (37.8)
28 (12.4)

203 (27.1)
25 (3.3)
69 (9.2)
310 (41.4)
141 (18.9)

2.07 (1.23–3.48)
1.72 (0.69–4.27)
1.67 (0.89–3.17)
1.26 (0.76–2.11)
REF

141 (62.7)
13 (5.8)
71 (31.6)

480 (64.2)
20 (2.7)
248 (33.2)

0.91 (0.64–1.30)
1.95 (0.91–4.19)
REF

53 (23.6)
143 (63.6)
29 (12.9)

145 (19.4)
438 (58.6)
165 (22.1)

2.03 (1.19 -3.47)
1.88 (1.18–2.97)
REF

68 (30.2)
29 (12.9)
128 (56.9)

180 (24.1)
85 (11.4)
483 (64.6)

1.38 (0.97–1.96)
1.32 (0.82–2.13)
REF

29 (12.9)
19 (8.4)
148 (65.8)

154 (20.6)
76 (10.2)
418 (55.9)

0.50 (0.32–0.77)
1.22 (0.71–2.10)
1.64 (1.18–2.28)

*

*
Complete-case analyses included 225 cases and 748 outpatient controls, for whom data were available on all model covariates. Supplemental documentation includes models
with imputed values to include all 241 cases and 817 outpatient controls included in this investigation.
†
Adjusted models incorporated a combination of the following factors, given covariates that were confounders for each exposure of interest: Sex, age (continuous, in years), race/
ethnicity, continuous SVI score, weight-for-age percentile, insurance status and the presence of underlying respiratory disorders.
‡
For each binomial underlying medical condition variable (respiratory system disorder, nonrespiratory system disorder, or previously healthy), the reference group was considered
to be those for whom the condition was absent.
AIAN indicates American Indian or Alaskan Native; MIS-C, multisystem inflammatory syndrome in children; NHPI, Native Hawaiian or Pacific Islander.

may explain 70% of variation in individual health outcomes,36 and
factors associated with a person’s residence and socioeconomic status have been identified as independent risk factors for outcomes
related to SARS-CoV-2 infection.13,36 Our study is consistent with
the findings of Javalkar et al13 showing Black race and higher SVI
to be independently associated with MIS-C. Our stratified analysis,
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

however, further demonstrated that SVI modified the association
between race and MIS-C such that non-Hispanic Black children
who resided in neighborhoods with lower SVI were more likely
to develop MIS-C compared with non-Hispanic White children;
however, this association was attenuated among children residing
in neighborhoods with moderate to high SVI. Our finding that SVI
www.pidj.com |
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TABLE 3. Association Between Race/Ethnicity and MIS-C, Stratified by SVI Quartile and Weight-for-Age
Percentiles (N = 1058)*
Characteristic
Low SVI (Score: 0 to 0.32)
Non-Hispanic Black
Hispanic/Latino of any race
Non-Hispanic White
Moderate to high SVI (Score: 0.33–1.0)
Non-Hispanic Black
Hispanic/Latino of any race
Non-Hispanic White
0–89th WAPCT
Non-Hispanic Black
Hispanic/Latino of any race
Non-Hispanic White
≥90th WAPCT
Non-Hispanic Black
Hispanic/Latino of any race
Non-Hispanic White

Cases

Controls

Adjusted OR (95% CI)

13 (52.0)
4 (16.0)
8 (32.0)

22 (17.5)
43 (34.1)
61 (48.4)

8.47 (2.24–32.03)
0.79 (0.21–2.96)
REF

68 (40.2)
81 (47.9)
20 (11.8)

181 (34.3)
267 (50.6)
80 (15.2)

1.76 (0.97–3.20)
1.49 (0.84–2.65)
REF

43 (41.0)
45 (42.9)
17 (16.2)

124 (30.0)
188 (45.4)
102 (24.6)

1.72 (0.87–3.40)
1.13 (0.58–2.20)
REF

38 (42.7)
40 (44.9)
11 (12.4)

79 (32.9)
122 (50.8)
39 (16.3)

2.36 (0.96–5.82)
1.25 (0.53–2.95)
REF

*
Children who were Native Hawaiian, Pacific Islander, Asian, American Indian, Alaskan Native, multiracial or other race were excluded from these stratified analyses due to
insufficient sample size. The complete-case multivariable SVI- and WAPCT-stratified analyses included 194 cases and 654 outpatient controls who were either non-Hispanic Black,
non-Hispanic White or Hispanic/Latino of any race.
MIS-C indicates multisystem inflammatory syndrome in children; SVI, social vulnerability index; WAPCT, weight-for-age percentile.

modified the association between race and MIS-C suggests the
importance of socioeconomic stress to the dysregulated immune
response characteristic of MIS-C, also seen in murine and nonhuman primate models of social stress associated with increased
immune-mediated inflammation.37,38 It is also possible that aggregate neighborhood measures of social factors may not fully capture the heterogeneity of individual and/or household-level social
risk factors within a neighborhood. SVI may not include the specific factors, such as household crowding, that may explain the
racial differences in risk for MIS-C among children who reside in
areas with lower SVI. Understanding community drivers of racial
disparities can promote equitable distribution of public health interventions, including COVID-19 vaccination, which is likely protective against MIS-C but has noted disparities in access and uptake
by race and ethnicity.39,40 These interventions must be tailored to
specific neighborhood-level risk factors and encourage a public
health and systems approach to reducing inequities and fostering
community health.41
This exploratory pilot investigation is subject to several
limitations. Control patients presenting to outpatient facilities
may be more likely to have symptomatic COVID-19 triggering
the testing, whereas many children developing MIS-C tend to
have asymptomatic or mild primary infection.42,43 Underlying respiratory diseases, like asthma, are associated with symptomatic
COVID-19;44 therefore, outpatient visits associated with acute
infection may have been more common for this outpatient control
population compared with MIS-C patients.45,46 Second, controls
may have more frequent engagement with preventive care services,
which may be linked to both higher burden of underlying disease
and lower social vulnerability. Third, MIS-C patients seeking care
at specialized pediatric hospitals may be drawn from a broader
geographic catchment area compared with outpatients, and we did
not match by zip code. Fourth, data collection for this investigation relied solely on data available in medical records with missing data for some variables; however, imputed and observed data
were comparable. Available data also did not leverage standardized MIS-C adjudication criteria at the point of data collection, as
this project was conducted during the first year of the pandemic,
concurrent with criteria development and implementation for the
Overcoming COVID-19 registry. Relatedly, alternative diagnoses
caused by coinfections cannot be ruled out, as 87 MIS-C patients
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in this study were not screened for other pathogens, and cultures
were less routinely ordered for early MIS-C cases. However, all
patient data subsequently underwent independent adjudication by
CDC coinvestigators, and only patients meeting CDC’s clinical
criteria for MIS-C were included as case-patients. Fifth, studies
in the US repeatedly show that while reporting of White race is
accurate, non-White race is less accurately reflected when using
electronic medical records.47–53 While race and ethnicity data were
obtained from the medical record, it is unknown whether this
information was self-indicated by the patient or recorded by providers. Sixth, we used census tracts extrapolated from zip-code
SVI data to define subjects’ neighborhoods, which has limitations
but has been used in prior studies.54–56 Finally, during enrollment,
it was not possible to frequency match four outpatient controls to
each case-patient by age group and site; however, we incorporated
age as a continuous variable in all adjusted models.

CONCLUSIONS
This investigation provides further evidence that non-Hispanic Black children appear to have higher likelihood of developing MIS-C after SARS-CoV-2 infection after adjustment for high
weight-for-age as a proxy for obesity and social vulnerability
measures. Most children with MIS-C are previously healthy so
underlying health conditions are unlikely to be major risk factors.
Investigations of other households, environmental and immunologic triggers for MIS-C are warranted to identify modifiable
factors for MIS-C prevention.
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Public Health Response to a Case of Paralytic Poliomyelitis
in an Unvaccinated Person and Detection of Poliovirus in
Wastewater—New York, June-August 2022
Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. MMWR Morbid
Mortal Wkly Rep 2022; 71: 1-5
On July 18, 2022, the New York State Department of Health (NYSDOH)
notified the Centers for Disease Control and Prevention (CDC) of detection
of poliovirus type 2 in stool specimens from an unvaccinated immunocompetent young adult from Rockland County, New York, who was experiencing acute flaccid weakness. The patient initially experienced fever, neck
stiffness, gastrointestinal symptoms, and limb weakness. The patient was
hospitalized with possible acute flaccid myelitis (AFM). Vaccine-derived
poliovirus type 2 (VDPV2) was detected in stool specimens obtained on
days 11 and 12 after symptom onset. As of August 10, 2022, related Sabinlike type 2 polioviruses were detected in wastewater (sewage) in the patient’s
county of residence and in neighboring Orange County up to 25 days before
(from samples originally collected for SARS-CoV-2 wastewater monitoring) and 41 days after the patient’s symptom onset. The last United States
(U.S.) case of polio caused by wild poliovirus occurred in 1979, and the
World Health Organization (WHO) Region of the Americas was declared
polio-free in 1994.
This report describes the second identification of community transmission of poliovirus in the U.S. since 1979. The previous instance, in 2005,
was a type 1 VDPV. The occurrence of this case, combined with the identification of poliovirus in wastewater in neighboring Orange County, underscores the importance of maintaining high vaccination coverage to prevent
paralytic polio in persons of all ages.
Based on the typical incubation period for paralytic polio, the presumed period of exposure occurred 7 to 21 days before the onset of paralysis. Epidemiologic investigation revealed that the patient attended a large
gathering 8 days before symptom onset and had not traveled internationally
during the presumed exposure period. No other notable or known potential
exposures were identified.
Upon notification of the poliovirus-positive specimen, CDC, NYSDOH, and local health authorities launched an investigation and response on
July 18, 2022. Activities included issuing a NYSDOH advisory on July 22
to increase health care provider awareness, enhancing surveillance for potentially infected persons, testing wastewater from Rockland and surrounding
New York counties, assessing vaccination coverage in the patient’s community, supplying inactivated polio vaccine (IPV) to county immunization
providers, and launching vaccination clinics throughout Rockland County.
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Enhanced surveillance defined persons under investigation (PUIs)
as those who met clinical criteria and who lived in or traveled to specific
counties or neighborhoods in New York or had international travel since
May 1, 2022. As of August 10, three additional persons were classified as
PUIs; available specimens from the PUIs (i.e., stool, cerebrospinal fluid,
serum, nasopharyngeal or oropharyngeal swabs) yielded negative poliovirus test results.
As of August 10, a total of 260 wastewater samples from treatment
plants in Rockland and Orange Counties, including samples originally collected for SARS-CoV-2 surveillance, were tested for poliovirus. Among
these samples, 21 (8%) yielded positive poliovirus test results using RTPCR and partial genome sequencing, including 13 from Rockland County
and eight from Orange County. Twenty specimens from wastewater samples
collected during May, June, and July were genetically linked to virus from
the patient’s stool samples; one additional sample, from April in Orange
County, was sequenced as poliovirus type 2, but the sequence was incomplete, precluding assessment of genetic linkage to the case.
According to the New York State Immunization Information System, 3-dose polio vaccination coverage among infants and children < 24
months of age living in Rockland County was 67.0% in July 2020 and
declined to 60.3% by August 2022, with zip code-specific coverage as low
as 37.3%. National coverage for IPV by age 24 months was 92.7% among
infants born during 2017-2018. The Rockland County Department of
Health launched a countywide catch-up vaccination effort on July 22, 2022.
Comment: At present, the origin of the VDPV2 detected in the
patient’s stool and in sewage samples remains unknown. Because the patient
had not traveled internationally during the potential exposure period, detection of VDPV2 in the patient’s stool samples indicates a chain of transmission within the U.S. originating with a person who received a type-2
containing oral polio vaccine (OPV) abroad; OPV was removed from the
routine immunization schedule in the U.S. in 2000. Genome sequence
comparisons have identified a link to vaccine-related type 2 polioviruses
recently detected in wastewater in Israel and the United Kingdom.
As of August 10, 2022, no additional poliomyelitis cases have
been identified, although the detection of VDPV2 genetically linked to
virus from the patient in wastewater specimens from two counties in
New York State over the course of greater than or equal to two months 2
months indicates community transmission and ongoing risk for paralysis
to unvaccinated persons. Until poliovirus eradication is achieved worldwide, importations of both wild polioviruses and VDPVs into the U.S.
are possible. This case highlights the risk for paralytic disease among
unvaccinated persons; all persons in the U.S. should stay up to date on
recommended IPV vaccination to prevent paralytic disease.
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